2.2 billion star antifungal drug Qilu, Hengrui went to follow the original research 8 percent market danger

Pharmaceutical Network June 5th, June 4th, Qilu Pharmaceuticals to copy 4 categories of injection acetic acid carpofen net listing application to obtain CDE acceptance, acceptance number CYHS2000377According to minet data, net sales of carpofffen with acetate in terminal injections in China's public medical institutions exceeded 2 billion yuan for the first time in 2019Carpofin net belongs to the echinoin drug, is a semi-synthetic lipopeptide, by inhibiting the synthesis of beta-(1,3)-D-glucan to perform bactericidal action, used to treat neutrophil sagtos, suspected fungal infections in patients with fever, and treatment of other treatment ineffective or intolerant of invasive clostherWith antifungal spectrum, excellent efficacy, high safety and so on, injection with acetate carpoffin net has become the whole body antifungal drug market ace drugs, widely marketed around the worldmeters net data show that in recent years, injection acetic acid carpoffin net in China's urban publichospitals, county-level public hospitals, urban community centers and township health hospitals (China's public medical institutions) terminal sales increased year by year, the annual growth rate reached double digits, in 2019 sales revenue of 2.23 billion yuan, an increase of 18.52 percent year-on-yearHengruiPharmaceutical seinesubmitted a supplementary application for net consistency evaluation for injecting acetic acid carpofin as early as August 2018, and again in November 2019, and is still in the "in the review and approval process (in the drug review center)"; In the snatch injection with acetic acid carpoffin net first rated track, Qilu and Hengrui you catch up with meSource: Minet database, CDENote: data statistics as of June 4, if there are omissions, welcome to point the finger!